What Can You Expect in 2026?
With iPSC therapies gaining real clinical momentum and regulatory pathways becoming clearer, the conversation is changing. There’s also a noticeable return of investor confidence with increased funding rounds and the return of big pharma in Bayer with Bluerock.Now, the question is how to deliver platforms reliably at scale and ensure long-term viability.
The 6th iPSC Drug Development Summit brings the community together to focus on what comes next. It takes a practical look at what it really involves to move from research into the clinic, and then beyond. You’ll hear from teams actively working on clinic-bound programs as they share honest lessons from their experience, including the challenges they’ve faced along the way.
The agenda covers the full journey, from early development through to later-stage considerations. It’s designed to give you a clearer sense of how to approach scale-up and prepare for regulatory expectations without overcomplicating the process.
More than just a meeting, it’s a chance to build a deeper understanding of the field and come away better equipped to move your own programs forward with confidence.
Unmissable Sessions
Proving Autologous iPSC Therapies in the Clinic
This session shares hard won experience advancing an autologous iPSC derived dopaminergic neuron therapy in Parkinson’s disease. It focuses on how early safety and engraftment data is being interpreted, see a clinical follow up data at this talk with Ron Cohen, Chief Executive Officer, Oryon Therapeutics
Advancing Hypoimmune iPSC Therapies Toward Clinical Proof
Exploring the clinical progress of a hypoimmune iPSC derived dopaminergic progenitor therapy, this talk highlights early safety and tolerability findings alongside longer-term biological activity signals with Luyan Jiao, Vice President, Nuwacell Biotechnologies
iPSC Derived Ocular Therapies Moving Toward Pivotal Trials
This clinical update connects preclinical engraftment and structural preservation with early functional readouts from iPSC derived retinal cell therapies, learn more with Yongting Wang, Head of Biology, Cell & Gene Therapy Research, Astellas Pharma
Scaling iPSC Manufacturing Without Losing Potency
Focused on execution at scale, this roundtable session examines how iPSC manufacturing can expand to commercial volumes while preserving potency and quality. It addresses and compared your challenges across comparability, process control, cost, and regulatory expectation with Cici Wang, Process Development Engineering, Vertex Pharmaceuticals
Divide & Conquer
Preclinical Development Track
Build Confidence Before You Commit to Scale
Explore how leading teams are strengthening early stage decisions around genome editing, cell line and donor selection, immune interaction, and functional QC to reduce downstream risk.
Featuring insights from: BlueRock Therapeutics, GC Therapeutics, Intellia Therapeutics, Astellas Pharma and more.
Process Development & CMC Track
Turn iPSC Science into GMP Ready Manufacturing
Learn how developers are aligning process development, analytics, and CMC strategy to support IND enabling and late stage manufacturing.
Featuring insights from: Vertex Pharmaceuticals, Cartherics, Vita Therapeutics, Aspen Neuroscience, and more.
Explore the Full Event Guide
- 25+ Industry leading speakers
- End-to-end coverage of iPSC drug development
- 2 dedicated tracks on preclinical development and process development and CMC
- Unrivaled Networking Opportunities with Clinical Companies Securing Investment
- See why this is the must-attend meeting for iPSC development
Speaking Companies in 2026:
Explore the Agenda
See where the bottlenecks really are and how teams are solving them.
This agenda goes beyond theory to highlight the decisions shaping real iPSC programs, from line selection and genome integrity to late stage scale up, comparability, and regulatory confidence.
Partner With Us
Shape the discussion at the point where priorities are being set.
This summit brings together the companies actively advancing iPSC therapies. Partnering here places your organization at the center of conversations that translate into program and collaborations.
Join the iPSC Community
Connect with a field that has moved past experimentation.
Meet a focused community of leaders working through the realities of clinical translation, manufacturing scale, and regulatory alignment. Biopharma and academics attend for free!